| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/29/2003 | EP1210349B1 PYRAZOLO 4,3-d]PYRIMIDINES |
| 01/29/2003 | EP1102761B1 Cyclopentabenzofuran derivatives and their use |
| 01/29/2003 | EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/29/2003 | EP1028948B1 Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| 01/29/2003 | EP0889884B1 1,2,4-triazine derivatives for the inhibition of protein glycosylation |
| 01/29/2003 | EP0888319B1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 01/29/2003 | EP0572560B1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 01/29/2003 | CN1394206A Novel vitamin D analogues |
| 01/29/2003 | CN1394205A Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1393446A 稠合吡唑化合物 Fused pyrazole compounds |
| 01/29/2003 | CN1393266A Slow-releasing hirudin medicine applied orally |
| 01/29/2003 | CN1393257A Medicine for treating cardiovascular disease |
| 01/29/2003 | CN1393252A Ointment for treating burn and its preparing process |
| 01/29/2003 | CN1393249A Chinese medicine for treating sino-atrial bundle syndrome caused by deficiency of vital function and essence of heart and kidney |
| 01/29/2003 | CN1393248A Extracting process and application of active component of pueraria root |
| 01/29/2003 | CN1393241A Onion extract and its preparing process |
| 01/29/2003 | CN1393239A Exterior-applied ointment for treating hypertension |
| 01/29/2003 | CN1393233A 'Jinma Tongmailing' capsule or injection for invigorating pulse |
| 01/29/2003 | CA2417631A1 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/28/2003 | US6512136 Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
| 01/28/2003 | US6512007 Treatment of inflammatory processes induced by excessive expression of the IL-6-induced acute phase proteins |
| 01/28/2003 | US6512001 D-proline derivatives |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511989 For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death |
| 01/28/2003 | US6511984 Neuropeptide Y antagonists |
| 01/28/2003 | US6511981 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 01/28/2003 | US6511979 Methods for treating conditions modulated by lactosylceramide |
| 01/28/2003 | US6511978 Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations |
| 01/28/2003 | US6511977 For preventing or treating cardiac arrhythmia or atrial arrhythmia |
| 01/28/2003 | US6511974 Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure |
| 01/28/2003 | US6511973 Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses |
| 01/28/2003 | US6511966 Administering for therapy of mitochondria medited disease |
| 01/28/2003 | US6511675 Dietary supplements |
| 01/28/2003 | US6511648 Vitronectin receptor antagonist pharmaceuticals |
| 01/28/2003 | US6511477 Administering encapsulated drugs such as antiarrythmia agents, so that there is preferential transportation due to particle sizes by lymphs; biodegradable time-release agents for prophylaxis of cardiovascular disorders |
| 01/28/2003 | CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/28/2003 | CA2124375C Compounds containing a fused bicyclic ring and processes therefor |
| 01/27/2003 | WO2002010127A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | CA2417427A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/24/2003 | WO2002016308A1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines |
| 01/24/2003 | WO2002010145A1 Urethane derivatives |
| 01/24/2003 | WO2002007735A1 Cardiac arrest fluid |
| 01/24/2003 | CA2417268A1 Urethane derivatives |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006950A2 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006465A1 Partial and full agonist of a adenosine receptors |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006453A1 Aminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006452A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 01/23/2003 | WO2003006421A1 Method for purifying n2-(1(s)-ethoxycarbonyl-3- phenylpropyl)-n6-trifluoroacetyl-l-lysine |
| 01/23/2003 | WO2003006070A2 Improved chelator conjugates |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006050A1 Preventives/remedies for brain edema |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006013A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003006002A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005998A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005970A2 Carvedilol polymorph |
| 01/23/2003 | WO2003005965A2 Modulators of ceramidase and methods of use based thereon |
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005959A2 Amphiphilic star-like macromolecules for drug delivery |
| 01/23/2003 | WO2003005958A2 Hypertension associated transcription factors and uses therefor |
| 01/23/2003 | WO2003005819A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002066978A3 Detection of compounds that modulate inflammatory responses |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002047456A3 Urotensin-ii receptor antagonists |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002043662A3 Dietary composition containing conjugated linoleic acid and calcium for improved health |
| 01/23/2003 | WO2002040498A3 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002022794A3 ENDOTHELIN CONVERTING ENZYMES AND THE AMYLOID βPEPTIDE |
| 01/23/2003 | WO2002022152A3 Use of deltorphin a and/or dermorphin h for protection against ischemia and reperfusion injury |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002017893A3 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 01/23/2003 | WO2002013798A3 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002009760A3 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 01/23/2003 | WO2002008177A2 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/23/2003 | WO2002000258A8 Medicinal compositions for angiogenic therapy |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | WO2001051472A9 New imidazole derivatives |
| 01/23/2003 | US20030018222 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |